Legend Biotech makes CAR-T cell therapies, a living drug engineered from a patient's own immune cells to fight blood cancer like multiple myeloma. Think of it as a personalized cancer assassin, not a pill.
Money comes from selling Carvykti (cilta-cel) for multiple myeloma, with revenue growing from USD 0.29B in 2023 to USD 1.03B in 2025. Gross margins are high at ~60%, but the company still loses money overall, with net losses of USD 0.30B in 2025.
Legend's CAR-T therapy is complex to manufacture and backed by a deep partnership with Johnson & Johnson's Janssen, giving it a strong position against Bristol Myers Squibb's Breyanzi and AbbVie's pipeline. However, competition from newer, cheaper or more conv
Key events, in time order
CARVYKTI Q1 2026 net trade sales were approximately $597 million, representing 52% growth compared to Q1 2025, with 36% U.S. growth and more than 200% ex-U.S. growth
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
